title: INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group.
abstract: OBJECTIVE
  To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).
  
  
  METHODS
  Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.
  
  
  RESULTS
  Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number of IVB injections per eye was 10.9 ± 6.4. At 5 years, the BCVA decreased from 20/150 (logMAR 0.9 ± 0.6) at baseline to 20/250 (logMAR 1.1 ± 0.7) (P = <0.0001). The mean CMT decreased from 343.1+ 122.3 μm at baseline to 314.7 ± 128.8 μm at 60 months of follow-up (P = 0.009). Geographic atrophy (GA) was observed at baseline in 47 (16%) of 292 eyes. By 5 years, GA developed or progressed in 124 (42.5%) of 292 eyes (P < 0.0001).
  
  
  CONCLUSIONS
  The early visual gains obtained from IVB were not maintained at 5 years of follow-up. In addition, IVB may play a role in the development or progression of GA.
authors.affiliation: *Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; †The Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; ‡The Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina; § Instituto de Cirugia Ocular, San Jose, Costa Rica; ¶University of Puerto Rico, San Juan, Puerto Rico; **Hospital La Fe, Universidad de Valencia, Spain; ††Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela; ‡‡OFTALMOS, Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina; §§Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico; ¶¶Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil; and ***MACULA D&T Diagnóstico, Tratamiento & Rehabilitación Visual, Lima, Peru.
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.forename: Andres F
authors.initials: AF
authors.lastname: Lasave
authors.forename: Lihteh
authors.initials: L
authors.lastname: Wu
authors.forename: Dhariana
authors.initials: D
authors.lastname: Acón
authors.forename: María H
authors.initials: MH
authors.lastname: Berrocal
authors.forename: Manuel
authors.initials: M
authors.lastname: Diaz-Llopis
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: Martin A
authors.initials: MA
authors.lastname: Serrano
authors.forename: Arturo A
authors.initials: AA
authors.lastname: Alezzandrini
authors.forename: Sergio
authors.initials: S
authors.lastname: Rojas
authors.forename: Mauricio
authors.initials: M
authors.lastname: Maia
authors.forename: Silvio
authors.initials: S
authors.lastname: Lujan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D057092:Geographic Atrophy / Q000175:diagnosis; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab